Parabilis Medicines Acquired | Healthcare M&A Deal

Parabilis Medicines has filed for an initial public offering, a pharmacy business in the United States, for $800 million. Parabilis Medicines develops Helicons, spiral-shaped peptide drugs aimed at “undruggable” oncology targets that conventional modalities cannot access, with early clinical data reported in desmoid tumors. The company is pursuing pharmacy acquisition and healthcare M&A opportunities to expand its platform beyond rare, non-cancerous growths into broader cancer indications. The IPO follows a $305 million Series F round and a potentially $2 billion research collaboration with Regeneron, after more than $800 million raised privately and nearly $600 million spent on drug research.